CASP10 Antibody

What is CASP10 and what cellular pathways does it participate in?

CASP10 (Caspase 10) is a critical enzyme in the apoptotic pathway, functioning as a mediator of programmed cell death. It belongs to the peptidase C14A family and contains two death effector domains (DED). At the molecular level, CASP10:

• Is involved in the activation cascade of caspases responsible for apoptosis execution

• Is recruited to both Fas- and TNFR-1 receptors in a FADD-dependent manner

• May participate in granzyme B apoptotic pathways

• Cleaves and activates effector caspases including CASP3, CASP4, CASP6, CASP7, CASP8, and CASP9

• Hydrolyzes specific small-molecule substrates such as Tyr-Val-Ala-Asp-|-AMC and Asp-Glu-Val-Asp-|-AMC

Dysregulation of CASP10 has been implicated in various diseases, including cancer, autoimmune disorders, and neurodegenerative conditions . Understanding these functions is essential for designing experiments targeting CASP10-related pathways.

What applications are suitable for CASP10 antibodies and what are the recommended dilutions?

CASP10 antibodies have been validated for several research applications with specific recommended dilutions:

It is recommended that researchers titrate these antibodies in their specific testing systems to obtain optimal results, as performance can be sample-dependent .

What are the optimal sample preparation methods for detecting CASP10 using antibodies?

For effective CASP10 detection:

• For Western blot analysis:

  • Use apoptosis-induced samples to enhance detection (staurosporine-treated Jurkat cells or apoptosis-induced HeLa cells serve as positive controls)

  • Prepare whole cell lysates using standard lysis buffers containing protease inhibitors

  • Include reducing agents in sample preparation as CASP10 contains critical cysteine residues

• For immunohistochemistry:

  • Perform antigen retrieval with TE buffer pH 9.0 for optimal results

  • Alternatively, citrate buffer pH 6.0 can be used for antigen retrieval

  • Use 4% paraformaldehyde fixation for 15-20 minutes for cultured cells

• For immunofluorescence:

  • Fix cells with 4% paraformaldehyde

  • Permeabilize with 0.1-0.5% Triton X-100

  • Block with 5% normal serum from the same species as the secondary antibody

These methods can be further optimized based on specific experimental requirements and sample types.

What molecular weight forms of CASP10 should be detected by antibodies?

Researchers should be aware of multiple CASP10 forms that may be detected:

• The calculated molecular weight of CASP10 is 59 kDa

• The most common observed molecular weight on Western blots is also 59 kDa

• Multiple isoforms exist with different molecular weights:

  • Pro-Caspase 10D (uncleaved): 59 kDa

  • Pro-Caspase 10A (uncleaved): 55 kDa

  • Cleaved forms: 47 kDa and 43 kDa

The expression pattern of these isoforms varies between cell types, with B-LCL and SEE T blasts primarily expressing uncleaved isoforms, while T-LCL mainly display cleaved counterparts . When interpreting experimental results, researchers should consider which isoforms are relevant to their specific research question.

How can researchers effectively study CASP10 mutations and their functional impacts?

To analyze CASP10 mutations and their functional consequences:

• Mutation identification strategy:

  • Sequence the entire coding region and all splice sites of the CASP10 gene

  • Focus on key domains: prodomain, p17 large protease subunit, and p12 small protease subunit

• Functional assessment methods:

  • Express tumor-derived or patient-derived CASP10 mutants in cell lines (e.g., 293 cells)

  • Measure apoptotic function using standardized apoptosis assays

  • Compare protein expression levels using Western blot analysis

• Protein expression analysis:

  • Assess CASP10 expression by Western blot using appropriate antibodies

  • Perform qRT-PCR to evaluate mRNA stability and expression levels

  • Analyze cleaved versus uncleaved forms to assess processing

For example, studies have shown that the p.C401LfsX15 variant results in abolished CASP10 expression due to RNA instability, while missense variants like p.V410I and p.Y446C do not disrupt CASP10 expression . These methodological approaches enable researchers to differentiate between pathogenic mutations and polymorphisms.

What are the critical considerations for studying CASP10 in autoimmune lymphoproliferative syndrome (ALPS)?

When investigating CASP10 in ALPS contexts, researchers should consider:

• Diagnostic framework:

  • Traditional classification grouped CASP10 mutations with FAS and FASLG mutations (ALPS-FAS/CASP10)

  • Recent evidence suggests CASP10 may be dispensable for FAS-mediated apoptosis

  • Compare findings with established ALPS-FAS cases to determine pathogenicity

• Methodological approach:

  • Generate T-blasts from peripheral blood mononuclear cells (PBMCs)

  • Establish immortalized B-lymphoblastoid and T-lymphoblastoid cell lines for long-term studies

  • Assess FAS-mediated apoptosis specifically, not just general apoptotic capacity

  • Evaluate FAS (CD95) surface expression to rule out compensatory mechanisms

• Variant interpretation challenges:

  • High allele frequency of some CASP10 variants in healthy populations

  • Inconsistent familial segregation patterns

  • Broad clinical spectrum complicating genotype-phenotype correlations

Recent research has challenged the role of CASP10 mutations in ALPS, with evidence that even complete CASP10 deficiency (homozygous p.C401LfsX15) does not impair FAS-mediated apoptosis , highlighting the importance of functional validation beyond sequence analysis.

How can researchers differentiate between polymorphisms and pathogenic variants of CASP10?

To distinguish between benign polymorphisms and disease-causing CASP10 variants:

• Population frequency analysis:

  • Check variant frequency in population databases

  • High frequency variants (like p.V410I and p.Y446C) are more likely polymorphisms

  • Rare variants affecting conserved domains warrant further investigation

• Structural and domain impact assessment:

  • Evaluate if the variant affects critical functional domains

  • Mutations in the catalytic domain (e.g., p.C401LfsX15 affecting the QACQG catalytic site) are more likely pathogenic

  • Assess conservation across species for the affected residues

• Functional validation protocol:

  • Express variant protein in appropriate cell models

  • Assess protein expression and stability by Western blot

  • Measure impact on FAS-mediated apoptosis specifically

  • Evaluate impact on downstream caspase activation

For example, research has shown that homozygous p.C401LfsX15 abolished CASP10 expression but surprisingly had no impact on FAS-mediated apoptosis function, challenging its classification as pathogenic for ALPS despite affecting a critical domain .

What are the best experimental models and controls for CASP10 antibody validation?

For rigorous CASP10 antibody validation:

• Positive controls:

  • Staurosporine-treated Jurkat cells (apoptosis induction)

  • Apoptosis-induced HeLa cells

  • Human endometrial cancer tissue (for IHC applications)

• Negative controls:

  • CASP10 knockout or knockdown cells (if available)

  • Cells expressing naturally occurring null mutations (e.g., homozygous p.C401LfsX15)

  • Pre-absorption with immunizing peptide for specificity confirmation

• Experimental validation approach:

  • Confirm specificity through multiple applications (WB, IHC, IF)

  • Verify molecular weight specificity in Western blot

  • Perform side-by-side comparisons with multiple antibodies targeting different epitopes

  • Include isotype controls for immunohistochemistry and immunofluorescence

These validation steps are critical for ensuring reliable and reproducible results in CASP10 research applications.

How can researchers investigate CASP10's role in non-Hodgkin lymphoma (NHL) pathogenesis?

For studying CASP10 in NHL development:

• Mutation screening strategy:

  • Analyze the entire coding region and splice sites of CASP10 in NHL samples

  • Focus on mutations in the prodomain, p17 large protease subunit, and p12 small protease subunit

• Functional characterization protocol:

  • Express tumor-derived CASP10 mutants in cell lines

  • Measure apoptotic function using standardized apoptosis assays

  • Correlate mutation status with clinical parameters and outcomes

• Methodological considerations:

  • Use appropriate control tissues (non-neoplastic lymphoid tissue)

  • Consider analysis across NHL subtypes for heterogeneity

  • Employ multiple antibodies targeting different CASP10 domains for comprehensive detection

Research has identified CASP10 mutations in 14.5% of NHL cases, with mutations distributed across different functional domains. Expression of these mutant proteins suppressed apoptosis, suggesting that inactivating mutations of CASP10 might contribute to NHL pathogenesis by disrupting normal cell death mechanisms .

How can researchers overcome common challenges in detecting CASP10 in various applications?

For addressing CASP10 detection issues:

• Western blot troubleshooting:

  • If signal is weak, induce apoptosis in positive control samples (staurosporine treatment)

  • Use freshly prepared samples as degradation can occur during storage

  • Try different lysis buffers that preserve CASP10 integrity

  • Adjust antibody concentration to 1:500 for stronger signals in challenging samples

• Immunohistochemistry optimization:

  • Test both TE buffer pH 9.0 and citrate buffer pH 6.0 for antigen retrieval

  • Extend incubation times with primary antibody at 4°C overnight

  • Use signal amplification systems for detecting low expression levels

  • Consider tyramide signal amplification for enhanced sensitivity

• Immunofluorescence enhancement:

  • Optimize fixation conditions (test both methanol and paraformaldehyde)

  • Adjust permeabilization conditions based on subcellular localization

  • Use confocal microscopy for improved signal-to-noise ratio

  • Consider colocalizing with other apoptotic markers for contextual validation

These strategies help overcome technical challenges while maintaining specificity in CASP10 detection.

What are the best methods to distinguish between isoforms and cleavage products of CASP10?

To effectively differentiate CASP10 isoforms and cleavage products:

• Gel electrophoresis approach:

  • Use gradient gels (8-15%) for better separation of closely sized fragments

  • Extend running time to enhance separation between 55-59 kDa isoforms

  • Include molecular weight standards specifically optimized for the 40-60 kDa range

• Antibody selection strategy:

  • Choose antibodies that target specific domains or cleavage sites

  • Use antibodies raised against the C-terminal region to detect full-length forms

  • Employ cleaved-specific antibodies for processed forms

  • Consider multiple antibodies in parallel for comprehensive detection

• Experimental induction protocol:

  • Compare unstimulated with apoptosis-stimulated samples to identify cleavage patterns

  • Include time-course experiments to track processing kinetics

  • Use cell type-specific positive controls (T-LCL for cleaved forms, B-LCL for uncleaved forms)

Research has shown that B-LCL and SEE T blasts primarily express the uncleaved isoforms Pro-Caspase 10D (59 kDa) and Pro-Caspase 10A (55 kDa), while T-LCL mainly display cleaved counterparts (47 kDa and 43 kDa) . This knowledge helps researchers interpret their results in a cell type-specific context.

How is CASP10 research evolving in relation to autoimmune and lymphoproliferative disorders?

Recent developments in CASP10 research include:

• Reassessment of CASP10's role in ALPS:

  • Traditional view included CASP10 mutations as causal in ALPS

  • Recent evidence suggests CASP10 is dispensable for FAS-mediated apoptosis

  • Current research focuses on clarifying discrepancies between genetic findings and functional outcomes

• Differential characteristics between ALPS-FAS/CASP10 and ALPS-U:

  • ALPS-U (undetermined genetic defects) patients show more complex phenotypes

  • Multi-organ involvement and higher positivity of autoimmune markers in ALPS-U

  • Treatment response differences between groups - ALPS-U often requires >2 lines of treatment

• Re-evaluation of previously reported pathogenic variants:

  • p.V410I and p.Y446C variants now considered polymorphisms

  • p.C401LfsX15 variant affects protein expression but not necessarily FAS-mediated apoptosis

  • Focus on comprehensive functional validation beyond sequence analysis

These evolving perspectives highlight the importance of combining genetic analysis with functional studies to accurately interpret CASP10 variants in clinical contexts.

What are the latest methodological approaches for studying CASP10 in cancer research?

Cutting-edge methods for investigating CASP10 in cancer include:

• Comprehensive mutational analysis:

  • Whole gene sequencing of CASP10 in tumor samples

  • Focus on non-Hodgkin lymphomas where mutations have been identified in 14.5% of cases

  • Analysis of mutations in different functional domains and correlation with disease features

• Expression-function relationship studies:

  • Combined analysis of protein expression and apoptotic function

  • Expression of tumor-derived mutants in cell models to assess functional impact

  • Evaluation of both intrinsic and extrinsic apoptotic pathway activation

• Clinical correlation approaches:

  • Assessment of CASP10 mutations in relation to treatment response

  • Correlation of mutation status with disease progression and prognosis

  • Potential for therapeutic targeting of apoptotic pathways in cases with CASP10 mutations

Research has shown that inactivating mutations of CASP10 might lead to the loss of apoptotic function and contribute to the pathogenesis of some human non-Hodgkin lymphomas, suggesting potential for targeted therapeutic approaches .

How can researchers reconcile contradictory findings regarding CASP10's role in apoptotic pathways?

To address conflicting evidence about CASP10 functions:

• Methodological standardization:

  • Adopt standardized apoptosis assays to enable cross-study comparison

  • Include multiple cell types to account for tissue-specific effects

  • Test both FAS-mediated and other apoptotic pathways separately

• Comprehensive pathway analysis:

  • Investigate potential compensatory mechanisms in CASP10-deficient systems

  • Assess redundancy between CASP8 and CASP10 in different cellular contexts

  • Evaluate impact on both upstream initiators and downstream effectors

• Integrated data approach:

  • Combine genetic, protein expression, and functional data

  • Consider variables like tissue type, activation conditions, and genetic background

  • Account for differences between in vitro and in vivo systems